Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
19 June, 2018 23:20 IST
Zydus Cadila gets USFDAs final nod for Phentermine HCl tablets
Source: IRIS | 30 Jun, 2017, 10.10AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Phentermine Hydrochloride Orally Disintegrating Tablets in strengths of 15 mg, 30 mg, and 37.5 mg.

The drug is used together with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, high cholesterol or diabetes and will be produced at the group’s formulations manufacturing facility at Moraiya in Ahmedabad.

Shares of the company gained Rs 3.55, or 0.68%, to trade at Rs 525.45. The total volume of shares traded was 16,403 at the BSE (10.03 a.m., Friday).





Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Sector
Cipla receives final approval for generic Sustiva - 19-Jun-2018 16:22
Wind power tariffs sustainable around Rs 3 a unit: Crisil Research - 19-Jun-2018 12:28
Dr. Reddy's Lab launches Levetiracetam in NaCl injection - 19-Jun-2018 12:23
Zydus Cadila receives tentative approval for Tadalafil tablets - 19-Jun-2018 12:22
Tata Power partners IDFC Bank for digitized solution in Mumbai - 19-Jun-2018 11:21
Tata Power partners IDFC Bank for digitized solution in Mumbai - 19-Jun-2018 11:21
Indian corporate leverage to improve on revenue, earnings growth: Moody's - 19-Jun-2018 11:15
ICICI Bank board appoints Sandeep Bakhshi as COO - 19-Jun-2018 11:00
Power Mech Projects bags order worth Rs 5 bn - 19-Jun-2018 10:22
Cords Cable wins bulk order worth Rs 472 mn - 19-Jun-2018 09:59
Glenmark Pharma gets approval for North California facility - 19-Jun-2018 09:55
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer